Piper Sandler Begins Coverage on Merus (NASDAQ:MRUS)

Piper Sandler began coverage on shares of Merus (NASDAQ:MRUS) in a research report report published on Thursday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $84.00 price target on the biotechnology company’s stock.

MRUS has been the subject of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $85.00 target price on shares of Merus in a report on Monday, December 2nd. Citigroup lifted their price objective on Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a report on Monday, December 9th. The Goldman Sachs Group initiated coverage on Merus in a report on Thursday, November 21st. They issued a “buy” rating and a $73.00 target price on the stock. Wells Fargo & Company began coverage on Merus in a research report on Friday, February 7th. They issued an “overweight” rating and a $91.00 price target for the company. Finally, Guggenheim reiterated a “buy” rating on shares of Merus in a research report on Wednesday. One research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Merus presently has an average rating of “Buy” and an average price target of $85.92.

Merus Stock Down 0.2 %

NASDAQ:MRUS opened at $40.20 on Thursday. Merus has a fifty-two week low of $37.77 and a fifty-two week high of $61.61. The firm’s fifty day simple moving average is $41.55 and its 200-day simple moving average is $47.17. The stock has a market cap of $2.75 billion, a PE ratio of -10.18 and a beta of 1.11.

Institutional Trading of Merus

Hedge funds and other institutional investors have recently bought and sold shares of the company. Boxer Capital Management LLC acquired a new stake in shares of Merus during the fourth quarter worth $79,895,000. Wellington Management Group LLP boosted its stake in Merus by 73.6% in the 3rd quarter. Wellington Management Group LLP now owns 2,887,514 shares of the biotechnology company’s stock worth $144,260,000 after buying an additional 1,224,573 shares during the last quarter. Avoro Capital Advisors LLC grew its holdings in Merus by 56.8% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company’s stock valued at $89,356,000 after buying an additional 770,000 shares during the period. FMR LLC increased its stake in shares of Merus by 10.4% during the 3rd quarter. FMR LLC now owns 6,873,926 shares of the biotechnology company’s stock valued at $343,421,000 after acquiring an additional 648,994 shares during the last quarter. Finally, Westfield Capital Management Co. LP purchased a new position in shares of Merus during the 3rd quarter worth about $30,399,000. 96.14% of the stock is owned by hedge funds and other institutional investors.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.